3. Taysha Gene Therapies Inc. (NASDAQ:TSHA)
Number of Hedge Fund Holders: 41
Market Capitalization: $1.38 billion
Share Price: $4.25
Taysha Gene Therapies, Inc. (NASDAQ: TSHA) has faced a weaker stock-market performance despite continued development of TSHA-102, its investigational gene therapy for Rett syndrome. The shares had declined approximately 19% in 2026 following a strong rally the previous year, according to the supplied market figures.
TSHA-102 is designed as a one-time treatment addressing the genetic basis of the disease. It delivers a functional form of MECP2, the gene associated with most Rett syndrome cases, using technology intended to regulate expression within individual cells.
That approach targets a substantial unmet need. Although an FDA-approved treatment for Rett syndrome already exists, a therapy addressing the underlying genetic cause would represent a different treatment proposition. Clinical evidence must establish whether TSHA-102 can deliver meaningful and durable benefits with acceptable safety.
Encouraging early findings have supported analyst interest. Wolfe Research reiterated an Outperform rating on September 17, citing the potential of the company’s pipeline.
The balance sheet gives the business resources to continue development. A June follow-on financing raised $230 million in gross proceeds, and cash and cash equivalents totaled $455.4 million at the end of the second quarter. Management expected those resources to support planned operations into the second half of 2028.
Spending is also rising as the program advances. Second-quarter research and development expenses reached $38.6 million, reflecting clinical activity and manufacturing preparations. That reinforces why financial capacity matters alongside trial results: a gene therapy developer must fund both the medicine and the processes needed to produce it.
Ranking rationale: Taysha Gene Therapies, Inc. (NASDAQ: TSHA) ranks third with 41 hedge-fund holders. Its Rett syndrome program and substantial cash position underpin its inclusion, while the concentration of value in TSHA-102 makes clinical durability, safety, and manufacturing execution particularly important.
